Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
Open accessThe DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Abstract
Objective: Our objective was to examine the mechanisms via which exenatide attenuates postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). Study Design: Seventeen T2DM patients (44 yr; seven females, 10 males; body mass index = 33.6 kg/m2; glycosylated hemoglobin = 7.9%) received a mixed meal followed for 6 h with double-tracer technique ([1-14C]glucose orally; [3-3H]glucose iv) before and after 2 wk of exenatide. In protocol II (n = 5), but not in protocol I (n = 12), exenatide was given in the morning of the repeat meal. Total and oral glucose appearance rates (RaT and RaO, respectively), endogenous glucose production (EGP), splanchnic glucose uptake (75 g − RaO), and hepatic insulin resistance (basal EGP × fasting plasma insulin) were determined. Results: After 2 wk of exenatide (protocol I), fasting plasma glucose decreased (from 10.2 to 7.6 mm) and mean postmeal plasma glucose decreased (from 13.2 to 11.3 mm) (P < 0.05); fasting and meal-stimulated plasma insulin and glucagon did not change significantly. After exenatide, basal EGP decreased (from 13.9 to 10.8 μmol/kg · min, P < 0.05), and hepatic insulin resistance declined (both P < 0.05). RaO, gastric emptying (acetaminophen area under the curve), and splanchnic glucose uptake did not change. In protocol II (exenatide given before repeat meal), fasting plasma glucose decreased (from 11.1 to 8.9 mm) and mean postmeal plasma glucose decreased (from 14.2 to 10.1 mm) (P < 0.05); fasting and meal-stimulated plasma insulin and glucagon did not change significantly. After exenatide, basal EGP decreased (from 13.4 to 10.7 μmol/kg · min, P = 0.05). RaT and RaO decreased markedly from 0–180 min after meal ingestion, consistent with exenatide's action to delay gastric emptying. Conclusions: Exenatide improves 1) fasting hyperglycemia by reducing basal EGP and 2) postmeal hyperglycemia by reducing the appearance of oral glucose in the systemic circulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown an improvement in hepatic glucose and lipid metabolism after GLP-1 injection [167,168] or GLP-1RA treatment [24,102,169,170,171] either in humans and animal studies.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [171]
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“Insulin secretion/insulin resistance (disposition) index was calculated as [ area under the curve (AUC)-insulin secretory rate (ISR)/ AUC-glucose] Matsuda index of insulin sensitivity (21, 22).”
MethodSelf-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 2×
“T2DM subjects have reduced circulating GLP-1 levels (3, 27) and a marked defect in the ability of the liver to dispose of an ingested glucose load (18, 28–30).”
BackgroundGastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Self-citationRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611 · cited 1×
“Glucagon-like peptide-1 (GLP-1) receptor agonists represent a new class of antidiabetic agents that have gained widespread use (2, 3).”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Research works printed but not linked: 1
- Samson, 2009, Exendin 4 down regulates gluconeogenic gene expression and gluconeogenesis in vivo and in isolated hepatocytes in vitro., Diabetes, 58, A3
Cited by
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“Increased insulin and inhibited glucagon secretion reduce basal HGP, reducing fasting plasma glucose concentration and enhancing HGP suppression after a meal (98,99).”
BackgroundSelf-citationAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Self-citationBrown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
“As noted above, the PPG-lowering effects observed with some GLP-1 receptor agonists (lixisenatide and exenatide, but not liraglutide) appear to be due primarily to slowing of gastric emptying [14,17,29–31].”
BackgroundGastaldelli, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70015-8 · Cited by 177
“It has been shown that GLP-1 secretion is blunted in diabetic or obese patients and contribute to impaired beta-cell function and that the treatment with GLP-1 analogs can normalize hyperglycemia by stimulating insulin secretion in diabetic patients and delaying gastric emptying [16].”
BackgroundSelf-citationAhrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationXiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Our group has demonstrated that the effect of exenatide on postprandial glucose fluxes in humans is acute and can be observed with just one dose 174,194 .”
Self-citationHiramoto, B., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A., Muftah, M., Flanagan, R., & Chan, W. W. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002820 · Cited by 94
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
“Consistent with previous studies in humans,((20,36,37)) we failed to observe any acute effect of EX on peripheral glucose uptake or glucose clearance.”
ResultSelf-citationEvolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Self-citationExploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities
Kanwal, A., Kanwar, N., Bharati, S., Srivastava, P., Singh, S. P., & Amar, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020331 · Cited by 88
“However, researchers are still exploring the exact mechanism of these drugs [87,88].”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“These studies show the potential of improved hepatic glucose metabolism for long-term glycaemic control [36,48].”
BackgroundGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Self-citationSolis-Herrera, C., Triplitt, C., Garduno-Garcia, J. D. J., Adams, J., DeFronzo, R. A., & Cersosimo, E. (2013) · Diabetes Care · doi:10.2337/dc12-2072 · Cited by 60
Self-citationTime for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Gastaldelli, A., & Marchesini, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.031 · Cited by 38
“Finally, liraglutide decreased hepatic glucose production and fasting hyperglycemia, improving hepatic insulin sensitivity, as already reported with exenatide [3,4,17].”
BackgroundSelf-citationLi, C., Liu, X.-J., Bai, L., Yu, Q., Zhang, Q.-M., Yu, P., & Yu, D. M. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-69 · Cited by 37
“However, the 2012 statement of the ADA and EASD included DPP4i as second-option medication when metformin fails, despite there was no specific preference compared with other oral agents (sulfonylurea and thiazolidinedione) in the same position [19].”
BackgroundLixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32
Once weekly exenatide: efficacy, tolerability and place in therapy
Wysham, C., Grimm, M. F., & Chen, S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12084 · Cited by 32
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
Self-citationGastaldelli, A., Brodows, R. G., & D'Alessio, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12199 · Cited by 24
Self-citationSharaiha, R. Z., Shukla, A. P., Sen, S., Chan, W. W., Broome, D. T., Anca, D., Abidi, W. M., Marya, N. B., Muniraj, T., Thosani, N. C., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.057 · Cited by 26
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
“In the same study, the replacement of glucagon during exenatide infusion blunted the suppressive effect of exenatide on EGP.13 On the other hand, GLP-1 infusion inhibits EGP in lean healthy men independently of islet hormones under conditions of pancreatic clamp.14,15 Gastaldelli et al.16 recently found that the acute…”
BackgroundInfluentialSelf-citationTobin, G. S., Cavaghan, M. K., Hoogwerf, B. J., & McGill, J. B. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12032 · Cited by 23
Gatford, K. L., Sulaiman, S. A., Mohammad, S. N. B., Blasio, M. J. D., Harland, M. L., Simmons, R. A., & Owens, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056553 · Cited by 23
“Improved whole-body insulin sensitivity is probably also due to improvements in hepatic insulin sensitivity, with lower post-prandial endogenous glucose production after or during exendin-4 treatment [79].”
BackgroundSadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
Mari, A., Prato, S. D., Ludvik, B. H., Miličević, Z., de la Peña, A., Shurzinske, L., Karanikas, C. A., & Pechtner, V. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12671 · Cited by 18
Gastaldelli, A., Nauck, M. A., & Balena, R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.05.001 · Cited by 15
“previously shown the improvement in ISR after 14 days of treatment with exenatide twice daily [34] and with sitagliptin [38].”
BackgroundSelf-citationPencek, R., Brunell, S. C., Li, Y., Hoogwerf, B. J., & Malone, J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2568 · Cited by 15
Can Circadian Eating Pattern Adjustments Reduce Risk or Prevent Development of T2D?
Harris, C., & Czaja, K. (2023) · Nutrients · doi:10.3390/nu15071762 · Cited by 13
“The reduction in insulin secretion occurs because people suffering from diabetes and obesity have fewer incretin hormones that increase insulin secretion [17].”
BackgroundAlatrach, M., Agyin, C., Adams, J. M., CHILTON, R. J., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.34 · Cited by 12
Self-citationSiler, S. Q. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03295-x · Cited by 12
STOLAR, M. W., Chen, S., & Grimm, M. F. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48837 · Cited by 12
Grossman, S. S. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0101-4 · Cited by 11
“The drug shares 53% sequence identity with human GLP-1 [13] and consequently binds with high affinity to GLP-1 receptors, thereby inducing all of its known glucoregulatory activities [19–21].”
Gastaldelli, A., Balas, B., Ratner, R. E., Rosenstock, J., Charbonnel, B. H., Bolli, G. B., Boldrin, M. N., & Balena, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12192 · Cited by 10
“The findings of this sub-study should be interpreted with caution: due to the exploratory nature of this study, statistical analyses were not specifically designed for hypothesis testing; the secondary endpoints were not part of the hierarchical testing used in the main study [19], there was no attempt to control for…”
BackgroundMethodSelf-citationYamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
NAFLD and Insulin Resistance: A Multisystemic Disease
Gastaldelli, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_4 · Cited by 4
Self-citationSilfvergren, O., Rigal, S., Schimek, K. M. S., Simonsson, C., Kanebratt, K. P., Forschler, F., Yesildag, B., Marx, U., Vilén, L., Gennemark, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.25.714139 · Cited by 3
“Restoration of glucose utilisation under pre-diabetic conditions is consistent with expected clinical responses to exenatide (40,41) .”
Cebra, C. K., Smith, C. C., Stang, B. V., & Tornquist, S. J. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12103 · Cited by 2
Honka, H., Gastaldelli, A., Pezzica, S., Peterson, R. E., DeFronzo, R. A., & Salehi, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15570 · Cited by 2
Self-citationAssociation of insulin resistance and non-alcoholic fatty liver disease
Mishina, E. Е., Mayorov, A. Y., Bogomolov, P., Liusina, E. O., & Bueverov, A. O. (2021) · Diabetes Mellitus · doi:10.14341/dm12234 · Cited by 2
Splanchnic Metabolism and Blood Flow In Man. PET Studies with Reference to Obesity and Diabetes
Honka, H. (2016) · UTUPub (University of Turku) · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
“reducing the appearance of oral glucose in the circulation [43].”
BackgroundUtilização da cúrcuma como tratamento da Diabetes Mellitus tipo 2: revisão de literatura
Tenorio, J. K. D. S., Santos, L. O. D., & Fidelix, M. S. P. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n4-100 · Cited by 1
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Self-citationLiraglutideas Adjunct Therapy in the Management of Obesity
Cersósimo, E., & Filho, D. R. (2015) · International Journal of Nutrology · doi:10.1055/s-0040-1705257
Belew, G. D. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Impatto del calo ponderale ottenuto tramite chirurgia bariatrica su GLP-1 e neuroplasticità in vivo
BONANINI, M. (2017) · Electronic Theses and Dissertations Repository (University of Pisa)
Metadata
- Authors
- Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., & DeFronzo, R. A.
- Affiliations
- Division of Diabetes (E.C., A.G., A.C., E.W., A.S., M.F., P.Z., C.T., N.M., R.A.D.), San Antonio, Texas 78229;
- Istituto di Fisiologia Clinica (IT)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, R. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06-01
- Volume
- 96
- Issue
- 6
- Pages
- 1763-1770
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987319592
- Cited by
- 50
- References
- 36
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 12 · 2012: 3
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
- puma.isti.cnr.it
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- exenatide, GLP-1 receptor agonists, type 2 diabetes, postprandial hyperglycemia, hepatic insulin resistance, endogenous glucose production, gastric emptying, hepatic glucose production, glucose metabolism, mixed meal tolerance test
- MeSH terms
- Exenatide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucagon, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Venoms, Postprandial Period, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.